Pamela Kunz, MD, is an expert in GI cancers and a courageous voice against gender discrimination and harassment in health care. In this episode, Kunz shares her story and provides guidance for those facing these types of challenges.

Intro :04 About Kunz :13 The interview 1:45 How did you get where you are now? 2:04 Can you tell us about your recent transition from Stanford to Yale? 3:40 How did you decide to start speaking out? 6:54 How do you guide women who find themselves in a similar situation? 9:11 What happened after you came out with this information? 11:32 If you don’t witness it, you may not know it’s happening 14:27 What are some of the challenges you encountered after going public? 17:16 Don’t read the comments 18:45 Did you tell Yale this would come out before transitioning from Stanford? 20:43 The importance of having support 22:40 Moving the needle 24:56 At what point should people be reporting these things? 28:58 If no one’s reporting, things won’t change 43:07 The importance of mentors and sponsors 34:24 Do you think this experience has changed you as a leader? 36:21 Kunz’s take-home message 40:48 How to reach Dr. Kunz 42:00

Pamela Kunz, MD, is an associate professor of medicine in the Division of Oncology at Yale University School of Medicine; leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center; and director of GI Medical Oncology within the Section of Medical Oncology.

We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Dr. Kunz can be reached on Twitter at @PamelaKunzMD and via email at [email protected]. Follow us on Twitter @HemOncToday @ShikhaJainMD

Disclosures: Jain reports she is a paid freelance writer for Lippincott. Kunz reports stock and other ownership interests in Guardant Health; consulting or advisory roles with Advanced Accelerator Applications, Ipsen, Lexicon and Novartis; and research funding from Advanced Accelerator Applications, Brahms (Thermo Fisher Scientific), Ipsen, Lexicon and Xencor.

Twitter Mentions